HeartBeam has enrolled the first patients in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The enrollment was conducted by Prof. Dr. Vladan Vukcevic at the University Clinical Center of Serbia in Belgrade, marking a critical step toward generating clinical data needed to expand the system's indication beyond arrhythmia assessment to include heart attack detection.
The importance of this development lies in the potential to transform cardiac emergency response. HeartBeam is creating the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians could potentially identify cardiac health trends and acute conditions and direct patients to appropriate care outside of a medical facility.
The technology's regulatory progress adds significance to this clinical trial. HeartBeam's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, and the 12-lead ECG synthesis software received clearance in December 2025. The company holds over 20 issued patents related to technology enablement, providing intellectual property protection for this innovative approach.
For patients, the implications are substantial. Current heart attack detection typically requires hospital-based equipment and trained personnel, creating delays that can impact outcomes. A portable system that can generate clinical-grade 12-lead ECGs outside medical facilities could enable earlier intervention, particularly in remote areas or during emergency transport. The technology could redefine cardiac health management by moving critical diagnostics closer to patients.
The medical technology industry is watching this development closely as it represents a potential shift in cardiac care delivery. Successful expansion of the HeartBeam System's indication to include heart attack detection would create new applications for portable ECG technology and potentially establish new standards for remote cardiac monitoring. The company's progress can be followed through its newsroom at https://ibn.fm/BEAT.
While this represents promising innovation, investors should note that certain statements are forward-looking and involve risks and uncertainties that may cause actual results to differ materially. These risks are detailed in the company's SEC filings, including its most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The full terms of use and disclaimers applicable to this information are available at http://IBN.fm/Disclaimer.
The ALIGN-ACS pilot study represents a crucial step toward validating whether this portable 3D ECG technology can accurately detect heart attacks in real-world settings. If successful, it could significantly impact how cardiac emergencies are identified and managed worldwide, potentially saving lives through earlier detection and intervention.
